Gliomas represent 86% of primary intracranial malig- nant tumors. Their most malignant form, glioblastoma multiform (GBM), is either astrocytic, oligodendrocytic, or includes a variety of other histo-pathological subtypes. The best non-invasive imaging modality for neuro- oncologic evaluation of the patients is MRI, which is used for differential diagnosis, biopsy guidance, therapeutic planning, and follow-up